Literature DB >> 7201320

N-methylformamide: antitumour activity and metabolism in mice.

A Gescher, N W Gibson, J A Hickman, S P Langdon, D Ross, G Atassi.   

Abstract

The antitumour activities of N-methylformamide, N-ethylformamide and formamide against a number of murine tumours in vivo (Sarcoma 180, M5076 ovarian sarcoma and TLX5 lymphoma) have been estimated. In all cases N-methyl-formamide had significant activity, formamide had marginal or no activity and N-ethylformamide had no significant activity. N-methylformamide and N-ethylformamide were equitoxic to the TLX5 lymphoma in vitro. Formamide was found as a metabolite in the plasma and urine of animals given N-methylformamide and N-ethylformamide, but excretion profiles do not support the hypothesis that formamide is an active antitumour species formed from N-alkylformamides. No appreciable metabolism of N-methylformamide occurred under a variety of conditions with liver preparations in vitro. N-methylformamide, but not N-ethylformamide or formamide, reduced liver soluble non-protein thiols by 59.8% 1 h after administration of an effective antitumour dose.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7201320      PMCID: PMC2011036          DOI: 10.1038/bjc.1982.136

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Studies on the mechanism of action and anticancer activity of N-methylformamide.

Authors:  H E SKIPPER; F M SCHABEL; V BINNS; J R THOMSON; G P WHEELER
Journal:  Cancer Res       Date:  1955-03       Impact factor: 12.701

2.  Retardation of growth of Ehrlich ascites tumor by formamides and related compounds.

Authors:  A FURST; W C CUTTING; H GROSS
Journal:  Cancer Res       Date:  1955-06       Impact factor: 12.701

3.  Pyrimidine studies. III. Effect of several compounds with antitumor activity on utilization of precursors for synthesis of nucleic acid pyrimidines.

Authors:  M L EIDINOFF; J E KNOLL; B J MARANO; D KLEIN
Journal:  Cancer Res       Date:  1961-11       Impact factor: 12.701

4.  The development and biochemical characterization of resistance to azaserine in a TA 3 ascites carcinoma.

Authors:  A C SARTORELLI; G A LePAGE
Journal:  Cancer Res       Date:  1958-05       Impact factor: 12.701

5.  Effects of N-methylformamide and related compounds in mouse sarcoma 180.

Authors:  D A CLARKE; F S PHILIPS; S S STERNBERG; R K BARCLAY; C C STOCK
Journal:  Proc Soc Exp Biol Med       Date:  1953-10

6.  A novel physiological role of liver glutathione as a reservoir of L-cysteine.

Authors:  T Higashi; N Tateishi; A Naruse; Y Sakamoto
Journal:  J Biochem       Date:  1977-07       Impact factor: 3.387

7.  Oxidative metabolism of some N-methyl containing xenobiotics can lead to stable progenitors of formaldehyde.

Authors:  A Gescher; J A Hickman; M F Stevens
Journal:  Biochem Pharmacol       Date:  1979-11-01       Impact factor: 5.858

8.  Studies of the metabolism of N-methyl containing anti-tumour agents: 14CO2 breath analysis after administration of 14C-labelled N-methyl drugs, formaldehyde and formate in mice.

Authors:  A Gescher; C Raymont
Journal:  Biochem Pharmacol       Date:  1981-06-01       Impact factor: 5.858

9.  Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin.

Authors:  J E Talmadge; M E Key; I R Hart
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

10.  Studies of the mode of action of antitumour triazenes and triazines-II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenes.

Authors:  A Gescher; J A Hickman; R J Simmonds; M F Stevens; K Vaughan
Journal:  Biochem Pharmacol       Date:  1981-01-01       Impact factor: 5.858

View more
  15 in total

1.  N-methylformamide affects spontaneous metastases of 3LL lines and increases natural killer activity of tumor-bearing mice.

Authors:  C Greco; D Del Bufalo; D Giannarelli; M Marangolo; M P Fuggetta; E Bonmassar; G Zupi
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

2.  Comparative hepatotoxicity and metabolism of N-methylformamide in rats and mice.

Authors:  K Tulip; J A Timbrell
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

3.  Different effects of sequential combinations of N-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice.

Authors:  G Arancia; C Leonetti; W Malorni; C Greco; G Formisano; M Marangolo; G Zupi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Enhancement of in vitro chemotherapeutic activity by dimethylsulfoxide.

Authors:  P J Tofilon; C M Vines; L Milas
Journal:  Clin Exp Metastasis       Date:  1985 Apr-Jun       Impact factor: 5.150

5.  In vivo metabolism of dimethylformamide and relationship to toxicity in the male rat.

Authors:  V Scailteur; R Lauwerys
Journal:  Arch Toxicol       Date:  1984-12       Impact factor: 5.153

6.  N-methylformamide-mediated enhancement of in vitro tumor cell chemosensitivity.

Authors:  P J Tofilon; C M Vines; L Milas
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 7.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Phase II trial of N-methylformamide in advanced head and neck cancer.

Authors:  W C Vogel; A A Forastiere; R B Natale; B J Takasugi; G Schnur
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

9.  Metabolism and hepatotoxicity of N,N-dimethylformamide, N-hydroxymethyl-N-methylformamide, and N-methylformamide in the rat.

Authors:  M Van den Bulcke; M T Rosseel; P Wijnants; W Buylaert; F M Belpaire
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

10.  Antitumor and antimetastatic activity of the differentiating agent N-methylformamide in murine tumor systems.

Authors:  M Iwakawa; P J Tofilon; N Hunter; L C Stephens; L Milas
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.